home All News open_in_new Full Article

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) […]


today 3 w. ago attach_file Other

attach_file Other
attach_file Politics
attach_file Other
attach_file Politics
attach_file Other
attach_file Events
attach_file Other
attach_file Events
attach_file Other
attach_file Other
attach_file Economics
attach_file Politics
attach_file Culture
attach_file Events
attach_file Other
attach_file Events
attach_file Other
attach_file Politics
attach_file Economics
attach_file Other


ID: 1497984530
Add Watch Country

arrow_drop_down